Childhood essential thrombocytosis [2]

Pediatric Blood and Cancer

Volumn 47, Issue 7, 2006, Pages 970-971

  Papageorgiou, Th ^a   Theodoridou, A ^a   Kourti, M ^a   Nikolaidou, S ^a   Athanassiadou, F ^a   Kaloutsi, V ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BUSULFAN; HYDROXYUREA; PIPOBROMAN;

CASE REPORT; CHILDHOOD DISEASE; ESSENTIAL THROMBOCYTOSIS; FEMALE; HUMAN; KARYOTYPE 46,XX; LETTER; LEUKEMOGENESIS; MEGAKARYOPOIESIS; MYELOPROLIFERATIVE DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOSIS;

CHILD, PRESCHOOL; FEMALE; HUMANS; HYDROXYUREA; THROMBOCYTOSIS;

EID: 33750472712     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20868     Document Type: Letter

References (8)

1. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: Pathogenesis, diagnosis, and management. Blood Rev 2001;15:121-131.
2. Hasle H. Incidence of essential thrombocythaemia in children. Br J Haematol 2000;110:751.
3. Jensen MK, de Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-139.
4. Dror Y, Blanchette VS. Essential thrombocythaemia in children. Br J Haematol 1999;107:691-698.
5. Finazzi G, Ruggeri M, Rodeghiero F, et al. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 2003;101:3749.
6. Randi ML, Putti MC. Essential thrombocythaemia in children: is a treatment needed? Expert Opin Pharmacother 2004;5:1009-1014.
7. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 2002;108:55-65.
8. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866.